With recent advances in proteomics, analytical and computational technologies, glycoproteomics -the global analysis of glycoproteins, is rapidly emerging as a sub-field of proteomics with high biological and clinical relevance. Glycoproteomics integrates glycoprotein enrichment and proteomics technologies to support the systematic identification and quantification of glycoproteins in a complex sample. The recent development of these techniques has stimulated great interest in applying the technology in clinical translational studies, in particular, protein biomarker research.
While glycomics is the study of glycome (repertoire of glycans), glycoproteomics focuses on studying the profile of glycosylated proteins, i.e. the glycoproteome, in a biological system. Considerable work has been done to characterize the sequences and primary structure of the glycan moieties attached to proteins (1) (2) (3) , and their structural alterations related to cancer (4-6). Recent reports have provided a comprehensive overview of the concept of glycomics and its prospective in biomarker research (7-10).
In contrast, this review is focused on recent developments in glycoproteomics techniques and their unique application and technical challenge to biomarker discovery.
Glycoproteomics in biomarker discovery and clinical study
Most secretory and membrane-bound proteins produced by mammalian cells contain covalently linked glycans with diverse structures (2) . The glycosylation form of a glycoprotein is highly specific at each glycosylation site and generally stable for a given cell type and physiological state. However, the glycosylation form of a protein can be altered significantly due to changes in cellular pathways and processes resulting from diseases, such as cancer, inflammation and neurodegeneration. Such diseaseassociated alterations in glycoproteins can happen in one or both of two ways: 1) protein glycosylation sites are either hypo, hyper or newly glycosylated and/or; 2) the glycosylation form of the attached carbohydrate moiety is altered. In fact, altered glycosylation patterns have long been recognized as hallmarks in cancer progression, in which tumor-specific glycoproteins are actively involved in neoplastic progression and metastasis (5,6,11,12). Sensitive detection of such disease-associated glycosylation changes and abnormalities can provide a unique avenue to develop glycoprotein biomarkers for diagnosis and prognosis. In addition, intervention in the glycosylation and carbohydrate-dependent cellular pathways represent a potential new modality for cancer therapies (6,11,13). Table 1 lists some of the FDA approved cancer biomarkers (14) that are glycosylated proteins or protein complexes.
Protein biomarker development is a complex and challenging task. The criteria and approach applied for developing each individual biomarker can vary, depending on the purpose of the biomarker and the performance requirement for its clinical application (15,16). In general, it has been suggested that the preclinical exploratory phase of protein biomarker development can be technically defined into four stages (17), including initial discovery of differential proteins; testing and selection of qualified candidates; verification of a subset of candidates; assay development and pre-clinical validation of potential biomarkers. Thanks to recent technological advances, mass spectrometry based glycoproteomics is now playing a major role in the initial phase of discovering aberrant glycoproteins associated with a disease. Glycoprotein enrichment techniques, coupled with multi-dimensional chromatographic separation and highresolution mass spectrometry have greatly enhanced the analytical dynamic range and limit of detection for glycoprotein profiling in complex samples such as plasma, serum, other bodily fluids, or tissue. In addition, candidate-based quantitative glycoproteomics platforms have been introduced recently, allowing targeted detection of glycoprotein candidates in complex samples in a multiplexed fashion, providing a complementary tool for glycoprotein biomarker verification in addition to antibody based approaches. It is clear that glycoproteomics is gaining momentum in biomarker research.
Glycoproteomics approaches
Glycoproteomic analysis is complicated not only by the variety of carbohydrates, but also by the complex linkage of the glycan to the protein. Glycosylation can occur at several different amino acid residues in the protein sequence. The most common and widely studied forms are N-linked and O-linked glycosylation. O-linked glycans are linked to the hydroxyl group on serine or threonine residues. N-linked glycans are attached to the amide group of asparagine residues in a consensus Asn-X-Ser/Thr sequence (X can be any amino acid except proline) (18). Other known, but less well studied forms of glycosylation include glycosylphosphatidylinositol anchors attached to protein carboxyl terminus, C-glycosylation that occurs on tryptophan residues (19) and S-linked glycosylation through a sulfur atom on cysteine or methionine (20,21). Our following discussion is focused on glycoproteomic analysis of the most common Nlinked and O-linked glycoproteins.
A comprehensive analysis of glycoproteins in a complex biological sample requires a concerted approach. While the specific methods for sample preparation can be different for different types of samples (e.g. plasma, serum, tissue, cell lysate), a glycoproteomics pipeline typically consists of glycoprotein or glycopeptide enrichment, multi-dimensional protein or peptide separation, tandem mass spectrometric analysis and bioinformatic data interpretation. For glycoprotein based enrichment methods, proteolytic digestion can be performed before or after glycan cleavage, depending on the specific workflow and enrichment methods used. For glycopeptide enrichment, proteolytic digestion is typically performed before the isolation step so that glycopeptides, instead of glycoproteins, can be captured. For quantitative glycoproteomics profiling, additional steps, such as differential stable isotope labeling of the sample and controls, are required. Figure 1 illustrates the general strategy for an integrated glycoproteomics analysis.
Glycoproteins or glycopeptides can be effectively enriched using a variety of techniques (see below). After the enrichment step, the workflow then splits into two directions: glycan analysis and glycoprotein analysis. The strategies for glycan analysis have been discussed in a number of reviews and will not be covered in this report. For glycoprotein analysis, bottom-up workflows ("shotgun proteomics" -peptide based proteomics analysis) (22) are still most common, providing not only detailed information of a glycoprotein profile, but also the specific mapping of glycosylation sites. It is notable that the reliable analysis of mass spectrometric data in glycoproteomic studies largely relies on bioinformatic tools and glyco-related databases that are available. An increasing number of algorithms and databases for glycan analysis have been developed and well documented in several recent reviews (23-25). For glycoprotein/glycopeptide sequence analysis, a large number of well-characterized and annotated glycoproteins can be found in the UniProt Knowledgebase (UniProtKB). In addition, many glycopeptide mass spectra are now available in the continually expanding PeptideAtlas library (26), which stores millions of high-resolution peptide fragment ion mass spectra acquired from a variety of biological and clinical samples for peptide and protein identification.
Ultimately, all the data obtained from different aspects of the workflow need to be merged and interpreted in an integrated fashion so that the full extent of glycosylation changes associated with a particular biological state can be better revealed. To the best of our knowledge, the complete glycoform analysis of any glycoprotein in a specific cell type under any specific condition has not yet been accomplished for any glycoprotein with multiple glycosylation sites. Current technology can define the glycan compliment and profile the glycoproteins, but is not capable of putting them together to define the molecular species present. To date, such integrated studies still remain highly challenging, even with advanced tandem mass spectrometry technologies and growing bioinformatic resources (25, (27) (28) (29) (30) .
Enrichment of the glycoproteome
Characterization of the glycoproteome in a complex biological sample such as plasma/serum or tissue, is analytically challenging due to the enormous complexity of protein and glycan constituents and the vast dynamic range of protein concentration in the sample. The selective enrichment of the glycoproteome is one of the most efficient ways to simplify the enormous complexity of a biological sample to achieve an in-depth glycoprotein analysis. Two approaches for glycoprotein enrichment have been widely applied: lectin affinity based enrichment methods (30) (31) (32) (33) (34) (35) and hydrazide chemistrybased solid phase extraction methods (36) (37) (38) (39) (40) (41) . Recent studies have demonstrated that the two methods are complementary and a very effective means for the enrichment of glycoproteins or glycopeptides from human plasma and other bodily fluids (37, 38, 42) . In addition, glycoprotein/glycopeptide enrichment using boronic acid (43,44), sizeexclusion chromatography (45), hydrophilic interaction (46) and a graphite powder micro-column (47) have been reported.
Lectin affinity enrichment is based on the specific binding interaction between a lectin and a distinct glycan structure attached on a glycoprotein (48,49). There are a variety of lectin species that can selectively bind to different oligosaccharide epitopes. For instance, concanavalin A (ConA) binds to mannosyl and glucosyl residues of glycoproteins (50); wheat germ agglutinin (WGA) binds to N-acetyl-glucosamine and sialic acid (51); and jacalin (JAC) specifically recognizes galactosyl (β−1,3) N acetylgalactosamine and O-linked glycoproteins (52). Lectin affinity enrichment has been designed to enrich glycoproteins with specific glycan attachment from plasma, serum, tissue and other biological samples through affinity chromatography and other methods. Multiple lectin species can also be combined to isolate multiple types of glycoproteins in complex biological samples (53-58). ConA and WGA, as well as JAC are often used together to achieve a more extensive glycproteome characterization (30, 33, 56, 58, 59 ). Several reports have demonstrated a multi-lectin column approach to achieve a global enrichment of glycoproteins with various glycan attachments from serum and plasma (30, 33, 58, 60, 61) . A recent study has developed a ''filter aided sample preparation''(FASP) based method, which allows highly efficient enrichment of glycopeptides using multi-lectins (62). To date, most of the work using lectin affinity for targeted glycoprotein enrichment has focused on N-glycosylation because the binding specificity of lectin for O-glycosylation is less satisfactory. To overcome such caveat, efforts have been made using serial lectin columns of Con A and JAC in tandem to isolate O-glycopeptides from human serum (34) .
A hydrazide chemistry-based method has been applied to isolate glycoproteins/glycopeptides through the formation of covalent bonding between the glycans and the hydrazide groups (36) . The carbohydrates on glycoproteins are first oxidized to form aldehyde groups, which sequentially react with hydrazide groups that are immobilized on a solid surface. The chemical reaction conjugates the glycoproteins to the solid phase by forming the covalent hydrazone bond. Although, conceptually, the majority of the glycoproteins in a biological sample can be captured using this method, the further analysis of the captured glycoproteins is practically limited by the method that can cleave glycoproteins or glycopeptides from the solid phase. Since there is a lack of efficient enzymes or chemicals that can specifically deglycosylate and/or release O-linked glycoproteins or glycopeptides from the solid phase, most of the studies have applied this method solely for N-linked glycoprotein analysis. PNGase F is the enzyme that can specifically release an N-glycosylated proteins or peptides (except those carrying α1→3 linked core fucose (37)) from its corresponding oligosaccharide groups. 
Mass spectrometric analysis of glycoproteome
Mass spectrometry, due to its high sensitivity and selectivity, has been one of the most versatile and powerful tools in glycoprotein analysis, to identify the glycoproteins, evaluate glycosylation sites and elucidate the oligosaccharide structures (55,71,72).
The utility of a top-down approach (intact protein based proteomics analysis) (73) for glycoprotein characterization in a complex sample is still technically challenging with the current technology. The most versatile and widely used current glycoproteomics methods are based on characterizing glycopeptides generated by the digestion of glycoproteins, analyzing either deglycosylated glycopeptides or intact glycopeptides with glycan attachment, as illustrated in Figure 1 . More details regarding mass spectrometric analysis of intact glycopeptides can be found in recent reviews (55,123). While great efforts have been made to apply a variety of mass spectrometry techniques to study both N-linked (31, 55, 85, 86, (111) (112) (113) (124) (125) (126) (127) (128) (129) and O-linked (89, 115, 118, 119, [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] glycopeptides, the interpretation of the fragment spectrum of an intact glycopeptide still requires intensive manual assignment and evaluation. A recent study has demonstrated the feasibility to develop an automated workflow for analyzing intact glycopeptides in mixtures (140) . In general, however, a high throughput, large scale profiling of intact glycopeptides in a complex sample still remains a challenge with current technology.
The analysis of de-glycosylated peptides requires the removal of glycan attachments from glycopeptides. Fortunately, for N-linked glycopeptides, the N-glycosidic bond can be specifically cleaved using the enzyme PNGase F, providing de-glycosylated peptides, which can then be analyzed directly using shotgun proteomics. The PNGase F-catalyzed de-glycosylation results in the conversion of asparagine to aspartic acid in the glycopeptide sequence, which introduces a mass difference of 0.9840 Da. Such distinct mass differences can be used to precisely map the N-linked glycosylation sites using high resolution mass spectrometers. Stable isotope labeling introduced by enzymatic cleavage of glycans in H 2
18
O has also been used to enhance the precise identification of N-glycosylation sites (32, 141, 142) . The removal of O-linked glycans is less straightforward, most assays rely on chemical de-glycosylation methods, such as trifluoromethansulfonic acid (143), hydrazinolysis (144), β-elimination (145), and periodate oxidation (34, 146) . The application of these methods suffers from a variety of limitations, such as low specificity for O-linked glycosylation, degradation of the peptide backbone, and modifications of the amino acid residues--all of which can complicate or compromise O-linked glycoproteomics analysis in a complex sample. Most of the large scale glycoproteomics studies using the de-glycosylation approach have been focused on N-glycoproteins, which are prevalent in blood and a rich source for biomarker discovery. O-glycosylation lacks a common core, consensus sequence and universal enzyme that can specifically remove the glycans from the peptide backbone, thus, is more challenging to analyze for large scale profiling.
After de-glycosylation, the glycopeptides can be treated and analyzed as stripped peptides using a shotgun proteomics pipeline. MS/MS fragment spectra with b-ions and y-ions generated from CID are searched against protein databases using search algorithms, such as SEQUEST (147) 
Glycoproteomics analysis in blood and other bodily fluids
An important target for blood-based diagnostic assays involves the detection and quantification of glycosylated proteins. Glycosylated proteins, especially N-linked glycoproteins, are ubiquitous among the proteins destined for extracellular environments (162), such as plasma or serum. A systematic and in-depth global profiling of the blood glycoproteome can provide fundamental knowledge for blood biomarker development, and is now possible with the development of glycoproteomics technologies. In the past few years, several large scale proteomics studies on profiling the glycoproteome of human plasma and serum have been reported (33, 34, 36, 37, 42, 60, 64, (163) (164) (165) , adding significant numbers of glycoproteins into the blood glycoproteome database. In one study (37) , immunoaffinity subtraction and hydrazide chemistry were applied to enrich N-glycoproteins from human plasma. The captured plasma glycoproteins were subjected to two-dimensional liquid chromatography (LC) separation followed by tandem mass spectrometric analysis. A total of 2053 different N-glycopeptides were identified, covering 303 non-redundant glycoproteins, including many glycoproteins with low abundance in blood (37) . In a different study, hydrazide chemistry based solid phase extraction method was applied to enhance the detection of tissue-derived proteins in human plasma (166) . Other studies have applied lectin affinity-based approaches to characterize the serum and plasma glycoproteome (33, 42, 165) . These studies provide detailed identification regarding the individual N-glycosylation sites using high resolution mass spectrometry. 
Glycoproteomics analysis of tissue and cell lysates
Protein glycosylation has been increasingly recognized as one of the prominent alterations involved in tumorigenesis, inflammation and other diseased states. The study of glycoproteins in cell and tissue carries great promise for defining biomarkers for diagnotic and therapeutic targets. The glycoproteomics studies in liver tissue (184, 185) and cell lines (186) 
Quantitative glycoprotein profiling
One of the major goals of clinical proteomics is to effectively identify dysregulated proteins that are specifically associated with a biological state, such as a disease. In the past decade, different quantitative proteomics techniques have been introduced and applied to study a wide variety of disease settings. These techniques are based on different mechanisms to facilitate mass spectrometric based quantitative analysis, including stable isotopic or isobaric labeling using chemical reactions (e.g. ICAT and iTRAQ) (192) (193) (194) , metabolic incorporation (e.g. SILAC) (195) and enzymatic reactions (e.g.
18
O labeling) (196, 197) ; as well as less quantitatively accurate label-free approaches (198, 199) . The overview and comparison of these quantitative techniques can be found in a number of reports in the literature and are not discussed in this review. Most of these isotopic labeling techniques can be adapted and utilized for glycoproteomics analysis to quantitatively compare the glycoproteome of a diseased sample to a control, thus revealing the glycosylation occupancy of individual glycosylation sites that may be involved in a disease. In addition to the well established labeling methods cited above, a number of more experimental labeling strategies have been described in the field of glycoproteomics. One study demonstrated the feasibility of using stable isotope labeled succinic anhydride for quantitative analysis of glycoproteins isolated from serum via hydrazide chemistry (36) . In a different report, heavy and light version of N-acetoxy-succinimide combining with lectin affinity selection was used to quantitatively profile serum glycopeptides in canine lymphoma and transitional cell carcinoma (200) . Stable isotope labeled 2-nitrobenzenesulfenyl was also used for chemical labeling in a quantitative glycoprotein profiling study on the sera from patients with lung adenocarcinoma (201) . O-Linked N-acetylglucosamine (O-GlcNAc) is an intracellular, reversible form of glycosylation that shares many features with phosphorylation (202) . Studies have suggested that O-GlcNAc may play an important role in many biological processes (203) . A quantitative study on O-GlcNAc glycosylation has been reported, in which a method termed quantitative isotopic and chemoenzymatic tagging (QUIC-Tag) was described using a biotin-avidin affinity strategy for O-GlcNAc glycopeptide enrichment and stable isotope labeled formaldehyde for mass spectrometric quantification (204) . Recently, the iTRAQ technique, combined with different glycoprotein enrichment approaches, has been utilized in several quantitative glycoproteomics studies. In the study of hepatocellular carcinoma (HCC), N-linked glycoproteins were enriched from HCC patients and controls using multi-lectin column and then quantitatively compared using iTRAQ to reveal the differential proteins associated with HCC (205) . In a different study, the approach of using narrow selectivity (206) . In a different approach, the SILAC technique allows incorporation of stable isotope labeled amino acids into proteins during cell culturing process (195) , and was applied to investigate the difference in cell surface Nglycoproteins between different cell types (63). A label-free approach has also been used for glycoproteomics profiling, including a method developed to profile intact glycopeptides in a complex sample (207) and a study that compares the plasma glycoproteome between psoriasis patients and healthy controls (208) .
Targeted glycoproteomics analysis
Mass spectrometry based targeted proteomics has recently emerged as a multiplexed quantitative technique that affords highly specific and candidate-based detection of targeted peptides/proteins in a complex biological sample (17, [209] [210] [211] [212] [213] . The technique is based on the concept of stable isotope dilution utilizing stable isotope labeled synthetic reference peptides, which precisely mimic their endogenous counterparts, to achieve targeted quantification (213) . Such techniques can be applied to target specific glycoproteins or glycopeptides, to precisely quantify the status of candidate glycosylation sites and assess the glycosylation occupancy at the molecular level.
However, it is technically impractical to use synthetic peptides to precisely mimic a large number of natural glycopeptides with intact a glycan moiety as internal standards because of the structure complexity and variation of the sugar chain. To overcome these technical obstacles, an alternative approach was proposed for targeted analysis of N-glycosylation occupancy, in which stable isotope labeled peptides were synthesized to mimic the de-glycosylated form of candidate glycopeptides as internal references (160) . It is known that the de-glycosylation step using PNGase F results in a conversion of asparagine to aspartic acid in the peptide sequence, introducing a mass difference of 0.984 Da. This phenomenon was utilized to design a synthetic peptide to mimic the endogenous N-linked glycopeptide in its de-glycosylation form with exact amino acid sequence of its endogenous counterpart and with 13 C and 15 N labeling on one of its amino acids (160) . Therefore, each matched pair of reference/endogenous candidate glycopeptides should share the same chromatographic and mass spectrometric characteristics, and can only be distinguished by their mass difference and isotopic pattern due to isotopic labeling. This design conceptually ensures that the synthetic internal standard of a candidate glycopeptide will be detected simultaneously with its endogenous form under the same analytical conditions, thus, minimizing the systematic variation and providing reliable quantification (213) . The strategy for targeted glycoproteomics analysis is schematically illustrated in Figure 2 .
The targeted glycoproteomics technique was first demonstrated to analyze N-
glycopeptides that were extracted from human serum using an integrated pipeline combining a hydrazide chemistry based solid phase extraction method and a datadriven LC MALDI TOF/TOF mass spectrometric analysis to quantify 21 N-glycopeptides in human serum (160) . A similar mass spectrometric platform was then applied in a different study to assess a subset of glycoprotein biomarker candidates in the sera from prostate cancer patients (214) . The targeted glycoproteomics analysis has also been demonstrated using a triple Q/linear ion trap instrument with the selected reaction monitoring (SRM, also referred to as multiple reaction monitoring -MRM) technique for highly sensitive targeted detection of N-glycoproteins in plasma (158) . The technique was applied to detect tissue inhibitor of metalloproteinase 1 (TIMP1), an aberrant glycoprotein associated with colorectal cancer, in the sera of colorectal cancer patients (215) using a tandem enrichment strategy, combing lectin glycoprotein enrichment followed by the method of stable isotope standards and capture by anti-peptide antibodies (SISCAPA), to enhance the detection of TIMP1 (215) . These studies demonstrate an integrated pipeline for candidate-based glycoproteomics analysis with precise mapping of targeted N-linked motifs and absolute quantification of the glycoprotein targets in a complex biological sample. Such targeted glycoproteomics can reach a detection sensitivity at ng/ml level for serum and plasma detection (158, (213) (214) (215) .
Conclusion remarks
The major challenge for a comprehensive glycoproteomics analysis arises not only from the enormous complexity and non-linear dynamic range in protein constituent in a 
